Summary:
A nationwide clinical trial led by researchers at the University of Colorado Boulder and Massachusetts General Hospital found that a free, online mindfulness program substantially reduces the risk of postpartum depression recurrence. The eight-session digital intervention, Mindful Mood Balance for Moms (MMB for Moms), cut the rate of depressive relapse by about 26% through six months postpartum among women at higher risk, offering an accessible, non-pharmacological prevention option for perinatal mental health.
Key Facts:
- 26% Reduction in Relapse: In a randomized controlled trial involving 500 pregnant participants from all 50 states, use of the digital mindfulness program was associated with a 26% lower rate of depression recurrence compared with usual care.
- Non-Pharmacological Access: The self-guided platform adapts Mindfulness-Based Cognitive Therapy (MBCT) for the perinatal period, combining educational modules, peer videos, and guided audio practices to address barriers such as stigma, cost, and limited local mental health providers.
- Protection Against Stress and Anxiety: In addition to reducing major depressive episodes, participants using the program reported meaningful decreases in everyday anxiety and perceived maternal stress during the study period.
Source: University of Colorado Boulder / Massachusetts General Hospital
Perinatal depression—depression that occurs during pregnancy or within the first year after childbirth—affects roughly one in five mothers. For those with a prior history of clinical depression, the risk of recurrence can be much higher. The condition often brings disrupted sleep, intense emotional distress, and challenges in forming secure parent–infant attachment.
Although antidepressant medication can reduce the risk of relapse, many pregnant women prefer psychological approaches. Safety concerns prompt about half of those taking antidepressants to reduce or stop medication during pregnancy, which raises relapse risk. Access to specialized perinatal psychotherapy is further limited by geographic provider shortages, high cost, and stigma, leaving many women without adequate prevention options.
To address this gap, an interdisciplinary team from the University of Colorado Boulder and Massachusetts General Hospital developed and tested Mindful Mood Balance for Moms, a scalable online program adapted from evidence-based MBCT. The trial, published in The Lancet Public Health, evaluated the platform’s effectiveness in preventing depressive relapse.
Testing Digital Mindfulness Across All 50 States
The randomized, single-blind trial enrolled 500 pregnant women across the United States who had a documented history of major depressive episodes and had used or were currently using antidepressants. None were in an active depressive episode at enrollment. Participants were randomized to one of two groups:
- The Intervention Cohort: Completed the 12-week, eight-session MMB for Moms program online, with periodic coaching check-ins to support engagement.
- The Control Cohort: Continued with their usual obstetric and psychiatric care without access to the digital program.
Researchers followed participants through six months postpartum, assessing depressive relapse as the primary outcome and measuring secondary outcomes such as depression symptom burden, maternal stress, and anxiety.
The curriculum integrates cognitive-behavioral techniques and guided mindfulness practices tailored for pregnancy and early parenting. Modules teach participants to identify automatic negative thought patterns, notice early warning signs of mood decline, cultivate self-compassion, and practice mindfulness in everyday caregiving moments like holding or feeding an infant.
“Expectant and new mothers should have accessible options to prevent depressive relapse,” said Sona Dimidjian, PhD, professor in the Department of Psychology and Neuroscience and director of the Renée Crown Wellness Institute at CU Boulder. “This trial used rigorous methods to show an effective non-drug option that can reach many women.”
Bridging Access Barriers in Perinatal Care
The program not only decreased clinical relapse risk but also reduced everyday anxiety and postpartum stress. Because about three-quarters of participants in both groups continued their prescribed antidepressants during the trial, results suggest digital mindfulness can serve as a meaningful adjunct to medication and as a stand‑alone option for those seeking non-pharmacological approaches.
Lee Cohen, MD, director of the Ammon-Pinizzotto Center for Women’s Health at Massachusetts General Hospital, noted the importance of digital delivery for expanding equitable access to maternal mental health care. “We have effective tools, but access has been limited. This program demonstrates a practical way to broaden prevention efforts for mothers nationwide,” Dr. Cohen said.
Long-Term Resilience for Families
Prior research on in-person MBCT has shown prolonged protection against depressive relapse for up to two years, so investigators expect that an effective digital adaptation could offer similarly durable benefits. The research team plans long-term follow-up studies to examine whether maternal participation in the program supports developmental and emotional outcomes for children born to mothers who completed the intervention.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by editorial staff.
About this research:
- Media Contact: Lisa Marshall
- Source: University of Colorado
- Image Credit: Image credited to Neuroscience News
- Original Research (Open Access): The Lancet Public Health (Oct 1, 2026). “Outcomes of Mindful Mood Balance for Moms, online mindfulness-based cognitive therapy for perinatal depressive relapse prevention in the USA: a two-arm, single-blind, pragmatic randomised clinical trial.” Authors: Sona Dimidjian et al.
- DOI: 10.1016/S2468-2667(26)00184-2
Abstract
Outcomes of Mindful Mood Balance for Moms, online mindfulness-based cognitive therapy for perinatal depressive relapse prevention in the USA: a two-arm, single-blind, pragmatic randomised clinical trial
Background
Effective, widely accessible interventions to prevent depressive relapse and reduce symptoms are essential for addressing perinatal depression. This trial evaluated MMB for Moms, a web-based MBCT program adapted for pregnant and postpartum women, compared with usual care, to determine its effect on depressive relapse and symptom burden.
Methods
This single-blind randomized clinical trial enrolled euthymic pregnant women with a history of recurrent depression who were on recent or current antidepressant medication. Recruitment ran from March 7, 2019, to July 8, 2020, with data collection completed September 12, 2021. Participants were assigned to MMB for Moms plus usual care or to usual care only. Primary outcomes were depressive relapse, assessed with the Mini International Neuropsychiatric Interview, and symptom burden measured with the Patient Health Questionnaire-9. Outcomes were tracked from baseline through six months postpartum across intervention, delivery, and postpartum phases. The trial was registered on ClinicalTrials.gov (NCT03623620).
Findings
Data from 500 participants (mean age 32 years, mean gestation 11.5 weeks) were analyzed by intention to treat. Of these, 249 were assigned to MMB for Moms and 251 to usual care; follow-up assessment data were available for 77% at three months and 78% at six months postpartum. Over the full trial period through six months postpartum, 33% of the MMB for Moms group experienced depressive relapse compared with 44% in usual care, representing a statistically significant reduction in relapse risk (hazard ratio 0.74; p=0.045). The MMB for Moms group also had greater reductions in depression symptom burden during the 12‑week intervention phase, though differences over the full trial period were smaller.
Interpretation
MMB for Moms lowered the risk of depressive relapse compared with usual care and reduced symptom burden during the intervention phase. As a scalable, non-pharmacological option, the program has potential public health implications for preventing perinatal depressive relapse.
Funding
Funded by the US National Institutes of Health and the US National Institute of Mental Health.